PROVISORISCHES ZWISCHENERGEBNIS DES ÖFFENTLICHEN UMTAUSCHANGEBOTS FÜR ALLE IM PUBLIKUM BEFINDLICHEN AKTIEN DER CASSIOPEA S.P.A.

EQS Group-Ad-hoc: Cassiopea S.p.A. / Schlagwort(e): Firmenübernahme            
COSMO PHARMACEUTICALS N.V. UND CASSIOPEA S.P.A. VERÖFFENTLICHEN PROVISORISCHES 
ZWISCHENERGEBNIS DES ÖFFENTLICHEN UMTAUSCHANGEBOTS FÜR ALLE IM PUBLIKUM        
BEFINDLICHEN AKTIEN DER CASSIOPEA S.P.A.                                       
                                                                               
16.11.2021 / 07:01 CET/CEST                                                    
Veröffentlichung einer Ad-hoc-Mitteilung gemäss Art. 53 KR                     
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.   
                                                                               
                                                                               
------------------------------------------------------------                   
Ad-hoc-Mitteilung gemäss Art. 53 KR                                            
                                                                               
                                                                               
                                                                               
Dublin, Irland und Lainate, Italien - 16. November 2021 - Cosmo Pharmaceuticals
N.V. (SIX: COPN) ("Cosmo") und Cassiopea S.p.A. (SIX: SKIN) ("Cassiopea") gaben
heute bekannt, dass während der Angebotsfrist des öffentlichen Umtauschangebots
in der Schweiz von Cosmo zum Erwerb aller sich im Publikum befindenden         
Namenaktien von Cassiopea, die am 15. November 2021 endete, nach den           
vorläufigen Ergebnissen Aktionäre 4,394,985 Cassiopea-Aktien angedient haben,  
was ca. 76.5% der sich im Publikum befindenden Cassiopea-Aktien entspricht, die
vom Angebot erfasst sind, was zusammen mit den Cassiopea-Aktien, die sich      
bereits im Besitz von Cosmo befinden, ca. 87.4% der derzeit ausgegebenen       
Cassiopea-Aktien entspricht.                                                   
                                                                               
Alessandro Della Cha, CEO von Cosmo: "Wir freuen uns, dass die Annahme des     
Angebots die Mindestschwelle von 50 % der Cassiopea-Beteiligung von Cosmo so   
deutlich überschritten hat. Nach dem Vollzug werden wir zügig mit der          
vollständigen Integration der beiden Unternehmen zum Vorteil aller Aktionäre   
fortfahren."                                                                   
                                                                               
Mauro Ajani, Vorsitzender von Cosmo sagte: "Ich bin sehr glücklich über dieses 
sehr gute Resultat. Die Zusammenlegung der Unternehmen zum jetzigen Zeitpunkt  
war für alle Beteiligten der richtige Schritt."                                
                                                                               
Cosmo wird in der definitiven Mitteilung des Zwischenergebnisses in            
Übereinstimmung mit den Bedingungen von Abschnitt B.8. des Angebotsprospekts   
vom 4. Oktober 2021 darauf eingehen, ob die anderen relevanten Bedingungen des 
Angebots erfüllt sind oder darauf verzichtet wurde. Die definitive Mitteilung  
des Zwischenergebnisses wird voraussichtlich am 18. November 2021              
veröffentlicht.                                                                
                                                                               
Nach dem Vollzug des Angebots beabsichtigt Cosmo, die Cassiopea-Aktien von der 
SIX Swiss Exchange zu dekotieren, wodurch Cassiopea voraussichtlich zu einer   
nicht kotierten Tochtergesellschaft im Mehrheitsbesitz von Cosmo wird.         
                                                                               
Eine Generalversammlung der Aktionäre wird stattfinden, um neue Mitglieder des 
Verwaltungsrats der Cassiopea zu wählen, nachdem Frau Diana Harbort und die    
Herren Jan De Vries und Oyvind Bjordal mit Wirkung zum Datum dieser            
Generalversammlung, die voraussichtlich vor Ende Januar 2022 stattfinden wird, 
zurückgetreten sind.                                                           
                                                                               
Diana Harbort, Chief Executive Officer von Cassiopea, wird, wie bereits        
mitgeteilt, nach Abschluss des Angebots von ihrer Funktion zurücktreten und zur
Präsidentin der neu gegründeten Dermatologie-Sparte von Cosmo ernannt werden,  
die die derzeitigen Geschäftsaktivitäten von Cassiopea umfassen wird.          
                                                                               
Weitere Informationen sind verfügbar unter                                     
https://www.cosmopharma.com/news-and-media/news-releases/2021/211116 und unter 
https://www.cassiopea.com/web-filter/ .                                        
                                                                               
                                                                               
                                                                               
About Cosmo Pharmaceuticals                                                    
Cosmo is a specialty pharmaceutical company focused on developing and          
commercialising products to treat selected gastrointestinal disorders and      
improve endoscopy quality measures through aiding the detection of colonic     
lesions. Cosmo has also developed medical devices for endoscopy and has        
recently entered into a partnership with Medtronic for the global distribution 
of GI Genius(TM) its artificial intelligence device for use in coloscopies and 
GI procedures. Cosmo has licensed Aemcolo(TM) to Red Hill Biopharma and is the 
licensee of BYFAVO(TM) (Remimazolam) for the US for procedural sedation, which 
it has sub-licensed to Acacia. For additional information on Cosmo and its     
products please visit the Company's website: www.cassiopea.com.                
                                                                               
                                                                               
                                                                               
About Cassiopea                                                                
Cassiopea is a specialty pharmaceutical company developing and preparing to    
commercialize prescription drugs with novel mechanisms of action (MOA) to      
address long-standing and essential dermatological conditions, particularly    
acne, androgenetic alopecia (or AGA) and genital warts. Cassiopea is investing 
in innovation that is driving scientific advancement in areas that have been   
largely ignored for decades. The portfolio comprises four unencumbered clinical
candidates, for which Cassiopea owns the worldwide rights. The Company's       
strategy is to leverage this expertise to optimize the commercial potential for
its products directly or with partners. For further information on Cassiopea,  
please visit www.cassiopea.com.                                                
                                                                               
                                                                               
                                                                             
                                                                             
Contact                                                                        
                                                                               
Niall Donnelly, CFO & Head of Investor Diana Harbort, CEO & Head of Investor   
Relations Relations                                                            
                                                                               
Cosmo Pharmaceuticals N.V. Cassiopea S.p.A.                                    
                                                                               
Tel: +353 1 817 03 70 Tel: +39 02 868 911 24,                                  
                                                                               
ndonnelly@cosmopharma.com dharbort@cassiopea.com                               
                                                                               
                                                                               
                                                                             
                                                                             
                                                                               
                                                                               
                                                                               
                                                                               
                                                                               
Disclaimer                                                                     
                                                                               
                                                                               
                                                                               
                                                                               
This communication (the "Communication") has been prepared by Cosmo            
Pharmaceuticals N.V. ('Cosmo" and together with its subsidiaries, "we", "us" or
the "Group") solely for informational purposes and has not been independently  
verified and no representation or warranty, express or implied, is made or     
given by or on behalf of any of the Group. Cosmo reserves the right to amend or
replace the Communication at any time, and undertakes no obligation to provide 
the recipients with access to any additional information. Cosmo shall not be   
obligated to update or correct the information set forth in the Communication  
or to provide any additional information. Nothing in this Presentation is, or  
should be relied upon as, a promise or representation as to the future.        
                                                                               
                                                                               
                                                                               
                                                                               
Certain statements in this Communication are forward-looking statements. By    
their nature, forward-looking statements involve a number of risks,            
uncertainties and assumptions that could cause actual results or events to     
differ materially from those expressed or implied by the forward-looking       
statements. These risks, uncertainties and assumptions could adversely affect  
the outcome and financial consequences of the plans and events described       
herein. Actual results may differ from those set forth in the forward looking  
statements as a result of various factors (including, but not limited to,      
future global economic conditions, changed market conditions, intense          
competition in the markets in which the Group operates, costs of compliance    
with applicable laws, regulations and standards, diverse political, legal,     
economic and other conditions affecting the Group's markets, and other factors 
beyond the control of the Group). Neither Cosmo nor any of its respective      
directors, officers, employees, advisors, or any other person is under any     
obligation to update or revise any forward-looking statements, whether as a    
result of new information, future events or otherwise. You should not place    
undue reliance on forward-looking statements, which speak of the date of this  
Communication. Statements  contained in this Communication regarding past      
trends or events should not be taken as a representation that such trends or   
events will continue in the future.                                            
                                                                               
                                                                               
                                                                               
                                                                               
 This Communication does not constitute or form part of, and should not be     
construed as, an offer or invitation or inducement to subscribe for, underwrite
or otherwise acquire, any securities of Cosmo, nor should it or any part of it 
form the basis of, or be relied on in connection with, any contract to purchase
or subscribe for any securities of the Group, nor shall it or any part of it   
form the basis of, or be relied on in connection with, any contract or         
commitment whatsoever. This Communication constitutes neither an offer to sell 
nor a solicitation to buy securities of Cosmo and it does not constitute a     
prospectus or similar notice within the meaning of articles 35 et seqq. or 69  
of the Swiss Financial Services Act or a prospectus pursuant to the laws of any
other jurisdiction. This Communication may be considered to be marketing       
material. The offer [and listing] will be made solely by means of, and on the  
basis of, a prospectus which is to be published. An investment decision        
regarding the publicly offered securities of Cosmo should only be made on the  
basis of the prospectus. The prospectus is expected to be published on or      
around 4 October 2021 and will be available free of charge at                  
https://www.cosmopharma.com/investors.                                         
                                                                               
                                                                               
United States of America                                                       
The securities described in this Communication have not been and will not be   
registered under the U.S. Securities Act of 1933, as amended (the "U.S.        
Securities Act"), or under any law of any state of the United States of        
America, and may not be offered, sold, resold, or delivered, directly or       
indirectly, in or into the U.S., except pursuant to an exemption from the      
registration requirements of the U.S. Securities Act and applicable state      
securities laws. Neither this document nor the exchange offer described herein 
constitutes an offer to sell or the solicitation of an offer to buy any        
securities in the U.S. or in any other jurisdiction in which such an offer or  
solicitation would be unlawful. Cosmo Pharmaceuticals N.V. will not register or
make a public offer of its securities, or otherwise conduct any public tender  
offer, in the U.S. In the U.S., this document is being provided to "qualified  
institutional buyers" (as defined in Rule 144A under the U.S. Securities Act)  
only on a confidential basis. Neither the United States Securities and Exchange
Commission nor any state securities commission in the United States has        
approved or disapproved the Offering of the shares or passed upon the adequacy 
or accuracy of the Prospectus. Any representation to the contrary is a criminal
offence in the United States. PROSPECTIVE PURCHASERS ARE HEREBY NOTIFIED THAT  
SELLERS OF COSMO SHARES MAY BE RELYING ON THE EXEMPTION FROM THE PROVISIONS OF 
SECTION 5 OF THE US SECURITIES ACT PROVIDED BY RULE 144A.                      
By tendering securities of Cassiopea S.p.A. into this offer, you will be deemed
to represent that you (x) (a) are not a U.S. person, (b) are not acting for the
account or benefit of any U.S. person, and (c) are not in or delivering the    
acceptance from, the United States or (y) you are a "qualified institutional   
buyer" as that term is used in Rule 144A under the U.S. Securities Act.        
United Kingdom                                                                 
This Communication is directed only at persons in the U.K. who (i) have        
professional experience in matters relating to investments falling within      
article 19(5) of the Financial Services and Markets Act 2000 (Financial        
Promotion) Order 2005 (the Order), (ii) are persons falling within article     
49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.")
of the Order or (iii) to whom it may otherwise lawfully be communicated (all   
such persons together being referred to as Relevant Persons). This             
communication must not be acted on or relied on by persons who are not Relevant
Persons. Any investment or investment activity to which this communication     
relates is available only to Relevant Persons and will be engaged in only with 
Relevant Persons.                                                              
Australia, Canada, Japan                                                       
This Communication is not addressed to shareholders of Cassiopea S.p.A. whose  
place of residence, seat or habitual abode is in Australia, Canada or Japan,   
and such shareholders may not accept the offer.                                
European Economic Area                                                         
The offer set out in this Communication (the Offer) is only being made within  
the European Economic Area (EEA) pursuant to an exemption under Regulation (EU)
2017/1129 (as amended and together with any applicable adopting or amending    
measures in any relevant member state (as defined below), the Prospectus       
Regulation), as implemented in each member state of the EEA (each a relevant   
member state), from the requirement to publish a prospectus that has been      
approved by the competent authority in that relevant member state and published
in accordance with the Prospectus Regulation as implemented in that relevant   
member state or, where appropriate, approved in another relevant member state  
and notified to the competent authority in that relevant member state, all in  
accordance with the Prospectus Regulation. Accordingly, in the EEA, the Offer  
and documents or other materials in relation to the Offer and the shares in    
Cosmo Pharmaceuticals N.V. (the Offeror Shares) are only addressed to, and are 
only directed at, (i) qualified investors (qualified investors) in the relevant
member state within the meaning of Article 2(1)(e) of the Prospectus           
Regulation, as adopted in the relevant member state, and (ii) persons who hold,
and will tender, the equivalent of at least EUR 100,000 worth of shares in     
Cassiopea S.p.A. (the Target Shares) in exchange for the receipt of Offeror    
Shares (collectively, permitted participants). This offer prospectus and the   
documents and other materials in relation to the Offer may not be acted or     
relied upon by persons in the EEA who are not permitted participants, and each 
Target shareholder seeking to participate in the Offer that is resident in the 
EEA will be deemed to have represented and agreed that it is a qualified       
investor or that it is tendering the equivalent of EUR 100,000 worth of Target 
Shares in exchange of Offeror Shares.                                          
Italy                                                                          
The offer set out in this Communication (the Offer) does not constitute a      
public offer nor a tender or exchange offer nor an advertisement of securities 
to the public in the Republic of Italy. Neither the Offer nor the COPN Shares  
have been registered with or cleared by the Commissione Nazionale per la       
Società e la Borsa ("CONSOB") (the Italian securities exchange commission),    
pursuant to Italian securities legislation. Neither the CONSOB nor any other   
Italian public authority has examined, approved, cleared or registered this    
Prospectus or will examine, approve, clear or register this Offer. Accordingly,
Italian residents cannot participate in the Offer nor may copies of this       
Communication or of any other document relating to the Offer be distributed or 
published in the Republic of Italy, either on primary and on secondary market. 
This Communication has not been prepared in accordance with the prospectus     
requirements nor the tender offer requirements provided for, or otherwise      
applicable in, Italy. Cosmo Pharmaceutical N.V. will not accept, directly or   
indirectly, any order relating to the Offer made in, or coming from, the       
Republic of Italy; any such order will be deemed null and void.                
General                                                                        
Cosmo Pharmaceuticals N.V.'s public tender and exchange offer for all publicly 
held shares of Cassiopea S.p.A. (the Offer) is not being made, directly or     
indirectly, in any country or jurisdiction in which such offer would be        
unlawful or otherwise violate any applicable law or regulation or which would  
require Cosmo Pharmaceuticals N.V. to make any amendment to the terms or       
conditions of the Offer, to make any additional application to, or to take any 
additional action with respect to, any governmental, regulatory or legal       
authority. It is not intended to extend the Offer to any such country or       
jurisdiction. Documents relating to the Offer may not be distributed in, or    
sent to, any such country or jurisdiction. Such documents may not be used for  
the purpose of soliciting purchases of Cassiopea S.p.A. securities by any      
person or entity resident or incorporated in such country or jurisdiction.     
This Communication is not for distribution in the United States, Canada,       
Australia, Japan or Italy. This communication does not constitute an offer to  
sell, or the solicitation of an offer to buy, securities in any jurisdiction in
which is unlawful to do so.                                                    
                                                                               
                                                                               
                                                                               
                                                                               
                                                                               
                                                                               
                                                                               
                                                                               
                                                                               
                                                                               
                                                                               
------------------------------------------------------------                   
                                                                               
                                                                               
Ende der Ad-hoc-Mitteilung                                                     
------------------------------------------------------------                   
                                                                               
                                                                               
                                                                               



Sprache:     Deutsch                   

Unternehmen: Cassiopea S.p.A.          

             Via Cristoforo Colombo 1  

             20045 Lainate             

             Schweiz                   

E-Mail:      info@cassiopea.com        

Internet:    https://www.cassiopea.com/

ISIN:        IT0005108359              

Börsen:      SIX Swiss Exchange        

EQS News ID: 1249263                   







                                            

Ende der Mitteilung  EQS Group News-Service



------------------------------------------------------------ 

1249263  16.11.2021 CET/CEST